VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 ...(s in animal studies. VIA will investigat...),Health

Date:10/29/2009

s in animal studies. VIA will investigate the possibility of using the THR beta agonist in combination with statins for the treatment of hypercholesterolemia. In addition, in animal studies, insulin sensitization and glucose lowering were observed making this compound a possible treatment of patients with type 2 diabetes in combination with other diabetes medications.

About DGAT1

DGAT1 (diacylglycerol acyl transferase-1) is an enzyme that catalyzes triglyceride synthesis and fat storage. Triglycerides are the principal component of fat, which is the major repository for storage of metabolic energy in the body. Overweight and obese individuals have significantly greater triglyceride levels, making them more prone to diabetes and its associated metabolic complications. DGAT1 inhibitors are believed to be an innovative class of compounds that modify lipid metabolism. In studies of obese animals, DGAT1 inhibitors have been shown to induce weight loss and improve insulin sensitization, glucose tolerance and lipid levels. These observations suggest DGAT1 inhibitors may have the potential to treat obesity, diabetes and dyslipidemia. VIA intends to identify potential clinical candidates from the compounds in this program and determine which may be moved into further preclinical development.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need by reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit:

SOURCE VIA Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
2. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
3. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
4. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
5. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
6. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
7. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
9. Onyx Pharmaceuticals to Host Investor Briefing Following ECCO/ESMO Oncology Congress
10. Biostar Pharmaceuticals, Inc. to Present at the Maxim Group Growth Conference on September 29 at 2:00pm ET
11. DUSA Pharmaceuticals to Present at the Maxim Group 3rd Annual Growth Conference